U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C26H43O9.Ca
Molecular Weight 1039.306
Optical Activity UNSPECIFIED
Defined Stereocenters 16 / 16
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of MUPIROCIN CALCIUM ANHYDROUS

SMILES

[Ca++].[H][C@@]2(C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)[C@H](O)[C@@H]1O)O[C@@]2([H])[C@@H](C)[C@H](C)O.[H][C@@]4(C[C@H]3CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)[C@H](O)[C@@H]3O)O[C@@]4([H])[C@@H](C)[C@H](C)O

InChI

InChIKey=HAXVBVDETFUQGV-LNQHITRNSA-L
InChI=1S/2C26H44O9.Ca/c2*1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;/h2*13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);/q;;+2/p-2/b2*16-13+;/t2*17-,18-,19-,20-,21-,24+,25-,26-;/m00./s1

HIDE SMILES / InChI
Molecular Formula C26H43O9
Molecular Weight 499.6142
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 1
Optical Activity UNSPECIFIED
Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68016712 | https://www.ncbi.nlm.nih.gov/pubmed/659331

Mupirocin (BACTROBAN®) is an antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyltransfer RNA (tRNA) synthetase. It also severely inhibits RNA synthesis. DNA and cell wall peptidoglycan synthesis are inhibited to a lesser extent and interference with these processes is considered to be a secondary effect. Mupirocin is bactericidal at concentrations achieved by topical administration.

Originator

Beecham Group
44
Curator's Comment: Beecham Group plc. is a predecessor of GlaxoSmithKline plc.

Approval Year

1987
111
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
 7.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
BACTROBAN

Approved Use

Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: S. aureus and S. pyogenes.

Launch Date

1987
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
634.22 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31536765
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MUPIROCIN plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
273 μg/mL
EXPERIMENT
https://www.degruyter.com/view/journals/ejnm/8/3/article-p139.xml
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MUPIROCIN plasma
Mus musculus
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
183.59 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31536765
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MUPIROCIN plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1100 μg × min/mL
EXPERIMENT
https://www.degruyter.com/view/journals/ejnm/8/3/article-p139.xml
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MUPIROCIN plasma
Mus musculus
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31536765
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MUPIROCIN plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.28 min
EXPERIMENT
https://www.degruyter.com/view/journals/ejnm/8/3/article-p139.xml
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MUPIROCIN plasma
Mus musculus
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
30 min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050591s034lbl.pdf
single, intravenous
 MUPIROCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050591s034lbl.pdf
single, intravenous
 MUPIROCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
252 mg single, intravenous
Overdose
Dose: 252 mg
Route: intravenous
Route: single
Dose: 252 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Other AEs: Headache, Rash...
Other AEs:
Headache (1.7%)
Rash (1.1%)
Nausea (1.1%)
Abdominal pain (< 1%)
Application site burning (< 1%)
Cellulitis (< 1%)
Dermatitis (< 1%)
Dizziness (< 1%)
Pruritus (< 1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Other AEs: Nausea, Headache...
Other AEs:
Nausea (4.9%)
Headache (3.6%)
Application site burning (3.6%)
Pruritus (2.4%)
Abdominal pain (1 patient)
Bleeding (1 patient)
Pain (1 patient)
Hives (1 patient)
Dry skin (1 patient)
Rash (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
2 % 1 times / day steady, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: steady
Dose: 2 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29728181/
unhealthy, children
n = 8
Health Status: unhealthy
Condition: tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus
Age Group: children
Sex: unknown
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/29728181/
Sources:
https://pubmed.ncbi.nlm.nih.gov/29728181/
AEs

AEs

AESignificanceDosePopulation
Nausea 1.1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Rash 1.1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Headache 1.7%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Abdominal pain < 1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Application site burning < 1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Cellulitis < 1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Dermatitis < 1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Dizziness < 1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Pruritus < 1%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 339
Health Status: unhealthy
Condition: various skin lesions
Age Group: adult
Sex: unknown
Population Size: 339
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Abdominal pain 1 patient
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Bleeding 1 patient
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Dry skin 1 patient
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Hives 1 patient
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Pain 1 patient
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Rash 1 patient
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Pruritus 2.4%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Application site burning 3.6%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Headache 3.6%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Nausea 4.9%
2 % 3 times / day steady, topical
Recommended
Dose: 2 %, 3 times / day
Route: topical
Route: steady
Dose: 2 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: secondarily infected eczema
Age Group: adult
Sex: unknown
Population Size: 82
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
911

CYP2B6
810

BSEP
402

MRP2
383

MRP3
157

MRP4
204
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BSEP
403
 no [IC50 >133 uM]
MRP2
475
 no [IC50 >133 uM]
MRP3
207
 no [IC50 >133 uM]
MRP4
238
 no [IC50 >133 uM]
CYP2B6
1001
 no
CYP2C8
965
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:7025
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7025
ChemicalBook
CB0689829
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0689829
MolPort
MolPort-003-666-882
https://www.molport.com/shop/molecule-link/MolPort-003-666-882
ZINC
ZINC000004102194
http://zinc15.docking.org/substances/ZINC000004102194
eMolecules
27678882
https://www.emolecules.com/cgi-bin/more?vid=27678882
eMolecules
31267427
https://www.emolecules.com/cgi-bin/more?vid=31267427
eMolecules
592210
https://www.emolecules.com/cgi-bin/more?vid=592210
PubMed

PubMed

TitleDatePubMed
On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus.
1978 Apr
Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.
1985 Apr
Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus.
2002 Feb
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Resistance to and synthesis of the antibiotic mupirocin.
2010 Apr
Patents

Patents

07737177
3
20010003007
3
JP2001500477A
122
JP2001521945A
47
JP2002511777A
414
JP2002541233A
400
JP2003515526A
462
JP2004059585A
3
JP2005162728A
3
JP2009501065A
33
JP2009526755A
447
JP2009541210A
79
JP2011526302A
67
JP2011528275A
455
JP2013543518A
3
JP3553083B2
49
JP4718445B2
36
JP4849764B2
75
JPH08269067A
3
JPH09157269A
3
JPH09510976A
15
JPS05432473A
3
JPS05490179A
3
JPS05815973A
3
JPS5270083A
3
JPS54103871A
3
JPS54103872A
3
JPS54106474A
3
JPS5412375A
3
JPS5412376A
3
JPS54125672A
3
JPS54125673A
3
JPS54148790A
3
JPS5432473A
3
JPS5459281A
3
JPS5490179A
3
JPS5815973A
3
US3977943
3
US4071536
3
US4289703
3

Sample Use Guides

In Vivo Use Guide
Apply a small amount of mupirocin (BACTROBAN®) cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days.
Route of Administration: Topical
In Vitro Use Guide
The MIC values for mupirocin were: 0.12 ug/ml (Staphylococcus aureus NCTC 6571), 0.12 ug/ml (Streptococcus pyogenes (A) 5936), 0.12 ug/ml (Streptococcus pneumoniae 1760).
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:59:17 GMT 2023
Edited
by admin
on Fri Dec 15 17:59:17 GMT 2023
Record UNII
870F25Y7EK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MUPIROCIN CALCIUM ANHYDROUS
Common Name English
CALCIUM PSEUDOMONATE
Common Name English
BACTROBAN NASAL
Common Name English
L-TALO-NON-2-ENONIC ACID, 5,9-ANHYDRO-2,3,4,8-TETRADEOXY-8-(((2S,3S)-3-((1S,2S)-2-HYDROXY-1-METHYLPROPYL)-2-OXIRANYL)METHYL)-3-METHYL-, 8-CARBOXYOCTYL ESTER, CALCIUM SALT (2:1), (2E)-
Common Name English
CALCIUM MUPIROCIN
Common Name English
Mupirocin calcium [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
870F25Y7EK
Created by admin on Fri Dec 15 17:59:17 GMT 2023 , Edited by admin on Fri Dec 15 17:59:17 GMT 2023
PRIMARY
CAS
104486-81-9
Created by admin on Fri Dec 15 17:59:17 GMT 2023 , Edited by admin on Fri Dec 15 17:59:17 GMT 2023
PRIMARY
PUBCHEM
6435927
Created by admin on Fri Dec 15 17:59:17 GMT 2023 , Edited by admin on Fri Dec 15 17:59:17 GMT 2023
PRIMARY
CHEBI
145818
Created by admin on Fri Dec 15 17:59:17 GMT 2023 , Edited by admin on Fri Dec 15 17:59:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID90883142
Created by admin on Fri Dec 15 17:59:17 GMT 2023 , Edited by admin on Fri Dec 15 17:59:17 GMT 2023
PRIMARY
Related Record Type Details
Structure of MUPIROCIN
PARENT -> SALT/SOLVATE
Structure of MUPIROCIN CALCIUM
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of MUPIROCIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966